Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before transport across the intestinal epithelium

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 1087-1092

  Hubatsch, Ina ^a   Lazorova, Lucia ^a   Vahlne, Anders ^b   Artursson, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIPEPTIDYL PEPTIDASE IV; GLYCINAMIDE; GLYCYLPROLINE; GLYCYLPROLYLGLYCINAMIDE; TRIPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; DIFFUSION; DRUG ACTIVATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; TRANSPORT KINETICS;

ADMINISTRATION, ORAL; ANTIGENS, CD26; ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CACO-2 CELLS; GLYCINE; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; OLIGOPEPTIDES;

EID: 14744276810     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.1087-1092.2005     Document Type: Article

References (25)

1. Andersson, E., P. Horal, A. Jejcic, S. Hoglund, J. Balzarini, A. Vahlne, and B. Svennerholm. 2005. Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glydne-amide. Antimicrob. Agents Chemother. 49:40-44.
2. Andersson, E., P. Horal, A. Vahlne, and B. Svennerholm. 2004. No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide. Antivir. Res. 61:119-124.
3. Artursson, P., and J. Karlsson. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175:880-885.
4. Balzarini, J., E. Andersson, D. Schols, P. Proost, J. van Damme, B. Svennerholm, P. Horal, and A. Vahlne. 2004. Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH2). Int. J. Biochem. Cell Biol. 36:1848-1859.
5. Bergstrom, C. A., M. Strafford, L. Lazorova, A. Avdeef, K. Luthman, and P. Artursson. 2003. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 46:558-570.
6. Brodin, B., C. U. Nielsen, B. Steffansen, and S. Frokjaer. 2002. Transport of peptidomimetic drugs by the intestinal di/tri-peptide transporter, PepT1. Pharmacol. Toxicol. 90:285-296.
7. Cogburn, J. N., M. G. Donovan, and C. S. Schasteen. 1991. A model of human small intestinal absorptive cells. 1. Transport barrier. Pharm. Res. 8:210-216.
8. Gulick, R. M. 2003. New antiretroviral drugs. Clin. Microbiol. Infect. 9:186-193.
9. Herrera-Ruiz, D., Q. Wang, O. S. Gudmundsson, T. J. Cook, R. L. Smith, T. N. Faria, and G. T. Knipp. 2001. Spatial expression patterns of peptide transporters in the human and rat gastrointestinal tracts, Caco-2 in vitro cell culture model, and multiple human tissues. AAPS PharmSci. 3:E9.
10. Hoglund, S., J. Su, S. S. Reneby, A. Vegvari, S. Hjerten, I. M. Sintorn, H. Foster, Y. P. Wu, I. Nystrom, and A. Vahlne. 2002. Tripeptide interference with human immunodeficiency virus type 1 morphogenesis. Antimicrob. Agents Chemother. 46:3597-3605.
11. Howell, S., A. J. Kenny, and A. J. Turner. 1992. A survey of membrane peptidases in two human colonic cell lines. Caco-2 and HT-29. Biochem. J. 284(Pt 2):595-601.
12. Lee, V. H. 2000. Membrane transporters. Eur. J. Pharm. Sci. 11(Suppl. 2):S41-S50.
13. Matter, K., M. Brauchbar, K. Bucher, and H. P. Hauri. 1990. Sorting of endogenous plasma membrane proteins occurs from two sites in cultured human Intestinal epithelial cells (Caco-2). Cell 60:429-437.
14. Myara, I., C. Charpentier, and A. Lemonnier, 1984. Prolidase and prolidase deficiency. Life Sci. 34:1985-1998.
15. Pehrson, P. O., A. Sonnerborg, A. Vahlne, and J. Spira. 2000. An initial safety and efficacy clinical trial of GPG-NH2, a tripeptide with a new anti-retroviral made of action. AIDS 14:S17-S18.
16. Rubas, W., N. Jezyk, and G. M. Grass. 1993. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm. Res. 10:113-118.
17. Rubino, A., and S. Guandalini. 1977. Dipeptide transport in the intestinal mucosa of developing rabbits. Ciba Found. Symp. 1977:61-77.
18. Sai, Y., Y. Kato, I. Tamai, A. Tsuji, A.-C. Svensson, and P. Artursson. 2003. Quantification of expression levels of intestinal transporters and application to oral drug delivery. Annu. Meet. Japanese Soc. Study Xenobiotics, abstr. 18.
19. Stenberg, P., U. Norinder, K. Luthman, and P. Artursson. 2001. Experimental and computational screening models for the prediction of intestinal drug absorption. J. Med. Chem. 44:1927-1937.
20. Su, J., E. Andersson, P. Horal, M. H. Naghavi, A. Palm, Y. P. Wu, K. Eriksson, M. Jansson, H. Wigzell, B. Svennerholm, and A. Vahlne. 2001. The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1. J. Hum. Virol. 4:1-7.
21. Su, J., M. H. Naghavi, A. Jejcic, P. Horal, Y. Furuta, Y. P. Wu, S. L. Li, W. W. Hall, L. Goobar-Larsson, B. Svennerholm, and A. Vahlne. 2001. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication. J. Hum. Virol. 4:8-15.
22. Tavelin, S., J. Grasjo, J. Taipalensuu, G. Ocklind, and P. Artursson. 2002. Applications of epithelial cell culture in studies of drug transport. Methods Mol. Biol. 188:233-272.
23. Tavelin, S., J. Taipalensuu, L. Soderberg, R. Morrison, S. Chong, and P. Artursson. 2003. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm. Res. 20:397-405.
24. Walker, D., D. T. Thwaites, N. L. Simmons, H. J. Gilbert, and B. H. Hirst. 1998. Substrate upregulation of the human small intestinal peptide transporter, hPepT1. J. Physiol. 507(Pt 3):697-706.
25. Walter, E., T. Kissel, and G. L. Amidon. 1996. The intestinal peptide carrier: a potential transport system for small peptide derived drugs. Adv. Drug Deliv. Rev. 20:33-58.